The constrained venture capital markets and difficult environment for IPOs, will make 2010 a big year for M&A transactions. The leaders in hot new software sectors will be swallowed up at a premium, along with entrepreneurs tired of running on the treadmill as they get closer to retirement, will drive more M&A transactions than ever. … Continue reading “Ringing in a New Year With Predictions for Hot Software Sectors”
Auction Holdings Receives $13,000,000 New Round
Feed Type Link http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=b01af95f-7a1a-4c41-8268-45660785e56c&Preview=1 Date 12/28/2009 Company Name Auction Holdings Mailing Address 38 Everett Street Allston, MA 02134 Company Description Auction Holdings is a Live online auction marketplace. Website http://www.auctionzip.com Transaction Type Venture Equity Transaction Amount $13,000,000 Transaction Round Undisclosed Proceeds Purposes Proceeds purposes were not disclosed. M&A Terms Venture Investor Commonwealth Capital Ventures Venture … Continue reading “Auction Holdings Receives $13,000,000 New Round”
SCVNGR Secures $4,000,000 New Financing Round
Feed Type Link http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=784722ee-a609-4abf-9d6f-37e7e0e85962&Preview=1 Date 12/28/2009 Company Name SCVNGR Mailing Address 580 Harrison Avenue Boston, MA 02118 Company Description SCVNGR is a geo-gaming platform that enables anyone to quickly and easily build location-based mobile games, tours, and interactive experiences that can be enjoyed from any mobile device. Website http://www.scvngr.com Transaction Type Venture Equity Transaction Amount … Continue reading “SCVNGR Secures $4,000,000 New Financing Round”
Jingle Networks Secures $6,750,000 Series E Funding
Feed Type Link http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=d965a69a-0c75-49c9-968b-5f486b73033e&Preview=1 Date 12/28/2009 Company Name Jingle Networks Mailing Address 50 California Street San Francisco, CA 94111 Company Description One day, one of our founders looked at his phone bill and thought, I hate paying for directory assistance. These fees are ridiculous. Website http://www.free411.com Transaction Type Venture Equity Transaction Amount $6,750,000 Transaction Round … Continue reading “Jingle Networks Secures $6,750,000 Series E Funding”
Trigemina Receives $305,000 New Funding
Feed Type Link http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=c9500d21-4bac-49d8-acd7-cfb35b70bc3a&Preview=1 Date 12/28/2009 Company Name Trigemina Mailing Address 809B Cuesta Drive Mountain View, CA 94040 Company Description Trigemina, Inc. exploits a newly discovered pathway for targeting the central nervous system, enabling vast new opportunities for treating acute and chronic pain. Website http://www.trigemina.com Transaction Type Venture Equity Transaction Amount $305,000 Transaction Round Undisclosed … Continue reading “Trigemina Receives $305,000 New Funding”
TriCipher Receives $3,000,000 New Round
Feed Type Link http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=8b75f63b-df1d-45e3-8d00-d94c33717418&Preview=1 Date 12/28/2009 Company Name TriCipher Mailing Address 750 University Avenue Los Gatos, CA 95032 Company Description TriCipher enables business processes and online products to be delivered through web portals at a lower risk, higher convenience and lower cost than ever before. Website http://www.tricipher.com Transaction Type Debt Transaction Amount $3,000,000 Transaction Round … Continue reading “TriCipher Receives $3,000,000 New Round”
ReVance Therapeutics Secures $25,620,000 Series D Funding
Feed Type Link http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=e9e79dac-682b-48a9-8e3a-ede6364c5504&Preview=1 Date 12/28/2009 Company Name ReVance Therapeutics Mailing Address 7555 Gateway Boulevard Newark, CA 94560 Company Description Revance is developing its lead compound, a topical botulinum toxin based on its cutting-edge drug delivery platforms and low molecular weight botulinum toxin. This product leverages Revance’s platform technologies to enhance patient tolerability of botulinum … Continue reading “ReVance Therapeutics Secures $25,620,000 Series D Funding”
Skybox Security Garners $2,000,000 Series D Funding
Feed Type Link http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=6daa0868-26b2-4d0d-a52f-f40e6b6c480c&Preview=1 Date 12/28/2009 Company Name Skybox Security Mailing Address 2077 Gateway Place San Jose, CA 95110 Company Description Skybox® Security, Inc. is a privately held company founded in 2002. The company is recognized as the pioneer in quantifying security risk and automating labor-intensive threat analysis and security control assessment processes. Website http://www.skyboxsecurity.com … Continue reading “Skybox Security Garners $2,000,000 Series D Funding”
Center’d Lands $1,875,000 New Funding
Feed Type Link http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=668cbba4-f41d-4ae7-97ee-f977475bbc94&Preview=1 Date 12/26/2009 Company Name Center’d Mailing Address 695 Oak Grove Avenue Menlo Park, CA 94025 Company Description The company operates an online community platform to assist people in getting to know other people in their local community. Website http://www.centerd.com Transaction Type Venture Equity Transaction Amount $1,875,000 Transaction Round Undisclosed Proceeds Purposes … Continue reading “Center’d Lands $1,875,000 New Funding”
Center’d Lands $1,875,000 New Funding
Feed Type Link http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=668cbba4-f41d-4ae7-97ee-f977475bbc94&Preview=1 Date 12/26/2009 Company Name Center’d Mailing Address 695 Oak Grove Avenue Menlo Park, CA 94025 Company Description The company operates an online community platform to assist people in getting to know other people in their local community. Website http://www.centerd.com Transaction Type Venture Equity Transaction Amount $1,875,000 Transaction Round Undisclosed Proceeds Purposes … Continue reading “Center’d Lands $1,875,000 New Funding”
Center’d Lands $1,875,000 New Funding
Feed Type Link http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=668cbba4-f41d-4ae7-97ee-f977475bbc94&Preview=1 Date 12/26/2009 Company Name Center’d Mailing Address 695 Oak Grove Avenue Menlo Park, CA 94025 Company Description The company operates an online community platform to assist people in getting to know other people in their local community. Website http://www.centerd.com Transaction Type Venture Equity Transaction Amount $1,875,000 Transaction Round Undisclosed Proceeds Purposes … Continue reading “Center’d Lands $1,875,000 New Funding”
Enjoy the holidays, and watch this space…
The boys and I will be taking some much needed time off for the next week and a half, so posting will be light in the main blog and News Xpress sections. But keep your eyes peeled, because over in the Xconomist Forum things are going to be hopping right on through the New Year. … Continue reading “Enjoy the holidays, and watch this space…”
Ringing in the New Year: Five San Diego Tech Companies Raise Cash in December
Venture fundraising came to life among for a number of San Diego’s high-tech companies in December, although the deals for the most part were relatively small. Here’s a roundup of recent deals that will no doubt help these startup founders rest a little easier over the holidays: —Daylight Solutions, the specialized maker of solid-state lasers … Continue reading “Ringing in the New Year: Five San Diego Tech Companies Raise Cash in December”
BSX Pays $22M in DOJ Settlement
Boston Scientific (NYSE:[[ticker:BSX]]) said yesterday that it has agreed to pay $22 million in a settlement related to a U.S. Department of Justice investigation of surveys conducted by the Natick, MA-based medical device firm’s subsidiary, Guidant. The company admitted no wrongdoing in the settlement. Reuters reported that the DOJ was investigating Guidant for paying doctors … Continue reading “BSX Pays $22M in DOJ Settlement”
ViaSat Sells Shares as Part of WildBlue Deal
ViaSat (NASDAQ: [[ticker:VSAT]]), the Carlsbad, CA-based satellite communications company raised $133 million in equity funding in December, according to a recent filing with the Securities and Exchange Commission. ViaSat spokesman Bruce Rowe tells me the company issued about 4.3 million shares for the stock component of the company’s $568 million stock-and-cash purchase of Colorado’s WildBlue … Continue reading “ViaSat Sells Shares as Part of WildBlue Deal”
Novexel Offers Exit to Atlas and Abingworth
Atlas Venture and Abingworth Management, two venture firms with local offices in Waltham, MA, are in line to exit their investments in French antibiotics developer Novexel, which announced yesterday it would be acquired by London-based drug giant AstraZeneca in a $505 million deal. AstraZeneca has agreed to pay $350 million in cash for all shares … Continue reading “Novexel Offers Exit to Atlas and Abingworth”
Readers’ Picks: Xconomy San Diego’s Top 5 Stories of 2009
There are many differences between this new world of online media and the old world of ink-on-paper that I used to inhabit. So many, in fact, that sometimes I feel like the earthling in the blockbuster “Avatar” who must take archery lessons and learn how to live in an alien culture. One of the most … Continue reading “Readers’ Picks: Xconomy San Diego’s Top 5 Stories of 2009”
MDRNA Grabs $1M Bridge Loan
MDRNA, the Bothell, WA-based company developing RNA interference technology, said today it has raised $1 million through a debt financing to ensure it has “sufficient resources” to meet its near-term goals of finding a partner or securing more financing in 2010. The company (NASDAQ: [[ticker:MRNA]]) said in a regulatory filing that it issued promissory notes … Continue reading “MDRNA Grabs $1M Bridge Loan”
Ambit Signs Big Deal With Astellas, Xenomics Alleges Fraud at Sequenom, Arena Seeks FDA Approval for Weight-Loss Drug & More San Diego Life Sciences News
Despite the fact that there are no snow days in San Diego, we still saw occasional flurries—of life sciences news—in the days before Christmas. Here at Xconomy, we’re wishing everyone happy holidays and an exponential New Year. —Scott Salka, the CEO of Ambit Biosciences told Luke the San Diego life sciences company pushed hard to … Continue reading “Ambit Signs Big Deal With Astellas, Xenomics Alleges Fraud at Sequenom, Arena Seeks FDA Approval for Weight-Loss Drug & More San Diego Life Sciences News”
Readers’ Picks for 2009: Terrafugia’s Maiden Flight, Kindle 2 Taps E Ink, Follica’s War on Baldness, & More
For the second year straight, our readers have made stories about the biotech startup Follica’s plans to treat baldness, Terrafugia’s street-legal aircraft, and the nonprofit One Laptop Per Child Foundation among Xconomy Boston’s five most popular posts for the year. What conclusions can we draw from this? Well, none. But I’ll speculate that some stories, … Continue reading “Readers’ Picks for 2009: Terrafugia’s Maiden Flight, Kindle 2 Taps E Ink, Follica’s War on Baldness, & More”
Editor’s Picks: The Best of 2009 From Xconomy Seattle
Every day in 2009, I got out of bed and thought about how to create excellent, original stories for Xconomy Seattle. So did my brother-in-arms, editor Greg Huang. We want Xconomy to be a source of original, in-depth, engaging content for you. We are always looking to dig up things about the local tech, biotech, … Continue reading “Editor’s Picks: The Best of 2009 From Xconomy Seattle”
Cell Therapeutics Dangles Exec Bonuses, Oncothyreon’s Turnaround Year, VLST Layoffs, & More Seattle-Area Life Sciences News
This was the last week of 2009 that anybody could realistically get deals done, and quite a few did. —Bothell, WA-based OncoGenex Pharmaceuticals (NASDAQ: [[ticker:OGXI]]) secured a partnership to develop its experimental prostate cancer treatment with Israel-based Teva Pharmaceutical, the generic drug giant. OncoGenex pulled in $60 million in upfront cash, but investors objected to … Continue reading “Cell Therapeutics Dangles Exec Bonuses, Oncothyreon’s Turnaround Year, VLST Layoffs, & More Seattle-Area Life Sciences News”
See Which Life Sciences Companies Are Getting The $25M State Tax Breaks
Quite a few of the companies we cover here at Xconomy received some good fortune this year right before the holidays. These 28 life sciences companies will pocket a total of $25 million in tax incentives, according to a statement from the Massachusetts Life Sciences Center. Gov. Deval Patrick, who staked a fair bit of … Continue reading “See Which Life Sciences Companies Are Getting The $25M State Tax Breaks”
Exponentials R Us: Seven Computer Science Game-Changers from the 2000’s, and Seven More to Come
Forty years ago, in 1969, Neil Armstrong left footprints on the surface of the moon. It was an extraordinary accomplishment. Also in 1969, with much less fanfare and at much less expense, Len Kleinrock’s programmer Charley Kline sent the first message over ARPANET. (The message was “lo” – the first two letters of “login.” Then … Continue reading “Exponentials R Us: Seven Computer Science Game-Changers from the 2000’s, and Seven More to Come”
Kakai Secures $7,500,000 Series A Financing Round
Feed Type Link http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=ba16b5f0-bd65-486e-9f15-8e9265910856&Preview=1 Date 12/24/2009 Company Name Kakai Mailing Address 2142 San Benito Drive Fremont, CA 94539 Company Description Kakai is developing an electronic books website service. Website http://www.kakai.com Transaction Type Venture Equity Transaction Amount $7,500,000 Transaction Round Series A Proceeds Purposes Proceeds purposes were not disclosed. M&A Terms Venture Investor Undisclosed
Kala Pharmaceuticals, Stealthy New Company Tied to MIT’s Bob Langer, Gets $2M
MIT’s famously inventive bioengineering professor, Bob Langer, is lending his expertise to yet another fledgling biotech company. Boston-based Kala Pharmaceuticals, which lists Langer on its board of directors, has secured a $2 million equity financing, according to a regulatory filing. Kala doesn’t have a website, and I haven’t been able to find any public statements … Continue reading “Kala Pharmaceuticals, Stealthy New Company Tied to MIT’s Bob Langer, Gets $2M”
Arena Loses Merck Collaboration After Clogged-Artery Drug Fails Clinical Trial
Somebody always delivers some bad news on the slow days before Christmas, and this year, it’s Arena Pharmaceuticals. The San Diego-based biotech company said today that pharma giant Merck has cancelled a research collaboration with Arena after an experimental drug for improving levels of the so-called “good” cholesterol failed to reach its goal in a … Continue reading “Arena Loses Merck Collaboration After Clogged-Artery Drug Fails Clinical Trial”
HyperMed Files for Chapter 11 Bankruptcy
Burlington, MA-based medical devices firm HyperMed has filed for Chapter 11 bankruptcy and ceased operations, the Boston Business Journal reports today. The weekly business newspaper, citing bankruptcy filings from Massachusetts District Court, wrote that the company has $2.4 million in debts and $1.1 million in assets. The startup had been marketing a device that used … Continue reading “HyperMed Files for Chapter 11 Bankruptcy”
pSivida Shares Boom as Eye Drug Passes Pivotal Trial
Shares of pSivida (NASDAQ: [[ticker:PSDV]]) rocketed more than 50 percent this morning on some positive clinical trial news. The Watertown, MA-based company, the developer of a treatment for an eye disorder related to diabetes, said its technology helped patients improve their vision after two years of follow up in a clinical trial. pSivida climbed 56 … Continue reading “pSivida Shares Boom as Eye Drug Passes Pivotal Trial”
In Development of Bio-Engineered Skin Tissue, Third Try is Charm for Advanced BioHealing
[Corrected 12/29/09, 3:40 pm. See below.] When it comes to commercializing a bio-engineered human skin substitute that could be used to treat diabetic ulcers and other tissue damage, Kathy McGee has the benefit of a long view. McGee tells me she arrived in San Diego from Ireland in 1992 to work for Advanced Tissue Sciences … Continue reading “In Development of Bio-Engineered Skin Tissue, Third Try is Charm for Advanced BioHealing”
India’s Innovation Front Lines 2009 (Part 2): Maharajas, Jewelry, and Economic Growth
Jaipur, December 22, 2009—I have come to Jaipur, a major tourist attraction, for the TiE Charter Member Annual Retreat. Some 250 charter members from across the 53 chapters of TiE are in attendance. These are some of the most successful entrepreneurs in the U.S., UK, India, Canada, Singapore, Malaysia, and Japan. The retreat begins with … Continue reading “India’s Innovation Front Lines 2009 (Part 2): Maharajas, Jewelry, and Economic Growth”
Announcing Xconomy Battle of the Tech Bands 3: Seattle vs. Boston
Are you tired of this whole East Coast vs. West Coast rivalry? Do you want it settled once and for all? What better way to do so than with a knock-down drag-out fight— with bass, drums, and guitars. That’s the idea behind Xconomy Boston’s third annual Xconomy Battle of the Tech Bands. The theme of … Continue reading “Announcing Xconomy Battle of the Tech Bands 3: Seattle vs. Boston”
Joule Biotechnologies Picks Site For Pilot Ethanol Plant in the Desert
Joule Biotechnologies has been busy since we last spoke to the company’s leadership around the time it first started talking publicly in July. The Cambridge, MA-based company, which develops fuels and chemicals in a process that mimics photosynthesis, has been advancing toward commercialization. I got the update from Bill Sims, the firm’s CEO. For starters, … Continue reading “Joule Biotechnologies Picks Site For Pilot Ethanol Plant in the Desert”
Oncothyreon CEO on Next-Generation Cancer Vaccines, Two Key Zymonites, and Serious Luck
Biotech companies can be resilient little animals, and one example in Seattle is Oncothyreon (NASDAQ: [[ticker:ONTY]]). This company looked like a goner a little over a year ago, when it was down to its last few months of cash and its stock was trading for less than a buck. Somehow, when his back was against … Continue reading “Oncothyreon CEO on Next-Generation Cancer Vaccines, Two Key Zymonites, and Serious Luck”
Founder of Adaptiva, Deepak Kumar, on Green-IT Strategy and Working with Microsoft
Seattle knows green—green trees, green ideas, and green innovation. As businesses rush to become more environmentally friendly, organizations like New York and London-based 1E and Seattle-based Verdiem have emerged as leaders in green-IT management. They offer systems that allow companies to cut off power to their computers remotely, saving energy and IT costs, and make … Continue reading “Founder of Adaptiva, Deepak Kumar, on Green-IT Strategy and Working with Microsoft”
Ambit, Buoyed by Astellas Deal, Attempting Rare Switch from Platform to Drug Developer
Ambit Biosciences made news last Friday when it pulled in $40 million through a partnership with Japan-based Astellas Pharma. We had the basic gist out fast that morning, but I gathered a lot more detail and insight during a follow-up conversation with Ambit CEO Scott Salka. It’s been a frenetic year at Ambit. The company … Continue reading “Ambit, Buoyed by Astellas Deal, Attempting Rare Switch from Platform to Drug Developer”
Biogen Drops Facet Bid, Aveo Reveals IPO Ambitions, Pfizer Partners with Adimab, & More Boston-Area Life Sciences News
New England’s drug developers and device makers are squeezing in a few more partnerships, acquisitions, financings, and strategic moves before the year’s end. —Acceleron Pharma, the Cambridge, MA-based biotech that’s building its own drug-making infrastructure rather that outsourcing the work, raised $10.9 million in equity financing, according to an SEC filing. $8 million comes from … Continue reading “Biogen Drops Facet Bid, Aveo Reveals IPO Ambitions, Pfizer Partners with Adimab, & More Boston-Area Life Sciences News”
The Top Five Advances From the Decade of Genomics
1. The Human Genome Project 2. Massively parallel DNA sequencing 3. Personalizing therapeutics via companion diagnostic tests (Herceptin, Gleevec, OncoDX, …) 4. Advanced diagnostics by blood biomarker analysis (e.g. fetal DNA/cells in mother’s blood) 5. The launch of the field of systems biology [Editor’s Note: This is part of a series of posts from Xconomists … Continue reading “The Top Five Advances From the Decade of Genomics”
ChaCha Search Secures $7,000,000 New Financing
Feed Type Link http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=57fbaf47-0117-4298-b31c-cb3f22e028e2&Preview=1 Date 12/23/2009 Company Name ChaCha Search Mailing Address 14550 Clay Terrace Blvd Carmel, IN 46032 Company Description ChaCha is available online and on your phone with information when you need it…any time, anywhere. Other services scan the Internet and return the thousands of pages that mathematically match your query. But, because … Continue reading “ChaCha Search Secures $7,000,000 New Financing”
23andMe Secures $16,780,000 Series B Round
Feed Type Link http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=5d947334-2bb7-443e-bc21-014c5bd7f2c5&Preview=1 Date 12/23/2009 Company Name 23andMe Mailing Address 1390 Shorebird Way Mountain View, CA 94043 Company Description 23andMe is focused on empowering individuals to access, explore, and better understand their genetic information, making use of recent advances in DNA analysis technologies and proprietary web-based software tools. Website http://www.23andme.com Transaction Type Venture Equity … Continue reading “23andMe Secures $16,780,000 Series B Round”
Curse.com Garners $6,000,000 Series B Funding
Feed Type Link http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=29a0f733-3c00-4a6c-97bc-396b7f26355e&Preview=1 Date 12/23/2009 Company Name Curse.com Mailing Address 351 California St. San Francisco, CA 94104 Company Description Curse is a massively multiplayer online game (MMOG) portal and community web site. Website http://www.curse.com Transaction Type Venture Equity Transaction Amount $6,000,000 Transaction Round Series B Proceeds Purposes Proceeds purposes were not disclosed. M&A Terms … Continue reading “Curse.com Garners $6,000,000 Series B Funding”
Webvanta Receives Series A Financing
Feed Type Link http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=1eb8c1aa-4082-4389-bb50-b4570100cbc6&Preview=1 Date 12/23/2009 Company Name Webvanta Mailing Address 708 Gravenstein Hwy Sebastopol, CA 95472 Company Description Webvanta provides a hosted service that dramatically reduces the time and effort required to build and deploy a dynamic web site. Website http://www.webvanta.com/team Transaction Type Venture Equity Transaction Amount Undisclosed Transaction Round Series A Proceeds Purposes … Continue reading “Webvanta Receives Series A Financing”
Telefónica Acquires Jajah for $206,000,000
Feed Type Link http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=9f079381-1c1e-4965-82d1-05d57bbf875c&Preview=1 Date 12/23/2009 Company Name Jajah Mailing Address 2513 Charleston Road Mountain View, CA 94043 Company Description JAJAH is a new type of phone company. We are dedicated to providing our customers with better phone service at a better price. It’s that simple. Website http://www.jajah.com Transaction Type M&A Transaction Amount $206,000,000 Transaction … Continue reading “Telefónica Acquires Jajah for $206,000,000”
Novartis AG Acquires Corthera for $120,000,000
Feed Type Link http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=581e359f-eb2b-4199-bddd-8436608c9921&Preview=1 Date 12/23/2009 Company Name Corthera Mailing Address 1660 S. Amphlett Blvd. San Mateo, CA 94402-2525 Company Description Corthera Inc., formerly BAS Medical, is a biopharmaceutical company committed to acquiring, developing and commercializing therapies for illnesses in the acute care setting. Corthera’s lead product candidate, relaxin, is currently being evaluated in a … Continue reading “Novartis AG Acquires Corthera for $120,000,000”
Seacoast Science Avoids VCs, Finds Other Money to Develop Tiny Chemical Sensors
I wanted to meet with the founders of Seacoast Science since I learned in late October that the Carlsbad, CA, startup is part of a government-sponsored initiative to embed tiny chemical sensors in cell phones. Seacoast’s technology is impressive: tiny microchips—about the size of the typeface on a postage stamp—each containing multiple individual sensors, or … Continue reading “Seacoast Science Avoids VCs, Finds Other Money to Develop Tiny Chemical Sensors”
“I Made It All The Way to IPO, And All I got Was This T-shirt!” Stories and Strategies for Surviving Your Exit
The MIT Enterprise Forum of the Northwest is organizing an event on Jan. 14 titled, “I made it all the way to IPO, and all I got was this T-shirt!”: Stories and Strategies for Surviving Your Exit. It will feature serial entrepreneurs as they share their stories and strategies to help you survive your exit … Continue reading ““I Made It All The Way to IPO, And All I got Was This T-shirt!” Stories and Strategies for Surviving Your Exit”
Xconomy’s Battle of the Tech Bands 3
A tech networking event that really rocks. Musicians from New England’s most innovative companies take on their Seattle competition—you pick the winners! Net ticket proceeds will be donated to Science Club for Girls and Year Up Boston. Date: Thursday, February 4, 2010 Location: Middle East Restaurant & Nightclub, 472 Massachusetts Ave, Cambridge Time: Doors open … Continue reading “Xconomy’s Battle of the Tech Bands 3”
Patent Issued to Vical and UW
San Diego-based Vical says today it has obtained a patent covering DNA vaccines for the sexually transmitted herpes simplex virus type 2 (HSV-2), the leading cause of genital herpes. Vical (NASDAQ: [[ticker:VICL]]) says it is in preclinical development of a HSV-2 vaccine in collaboration with the University of Washington School of Medicine, which also is … Continue reading “Patent Issued to Vical and UW”
AVI Biopharma Drug Shows Hint of Effect Against Muscular Dystrophy In Small Study
Bothell, WA-based AVI Biopharma (NASDAQ: [[ticker:AVII]]) is trying to develop the first treatment to correct an underlying molecular abnormality in boys with Duchenne Muscular Dystrophy, and after taking an early peek at a small clinical trial, the drug appears to be doing what it’s supposed to do in at least one patient. The preliminary results … Continue reading “AVI Biopharma Drug Shows Hint of Effect Against Muscular Dystrophy In Small Study”
Livemocha Scores $8M Series B Round, Looks to Expand Globally with New Partnerships
Now here’s an interesting deal from a company we’ve had our eye on for a while. Bellevue, WA-based Livemocha, which runs a popular language-learning website, announced today it has raised $8 million in Series B financing, led by new investor August Capital in Menlo Park, CA. Existing venture investor Maveron, based in Seattle, also participated … Continue reading “Livemocha Scores $8M Series B Round, Looks to Expand Globally with New Partnerships”